Kick-off meeting held for Reforgene's Guangdong Provincial Key R&D Program project
On November 30, 2023, under the guidance of the Guangdong Provincial Department of Science and Technology, the kick-off meeting of the Guangdong Provincial Key R&D Program project "Gene Editing Hematopoietic Stem Cell Products and R&D Platform for Treating Blood Genetic Diseases", led by Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene"), was successfully held.
As the leading unit of the project, Reforgene aims to build a gene editing hematopoietic stem cell R&D platform for treating blood genetic diseases, carry out systematic arrangements for gene therapy of blood genetic diseases including thalassemia, and accelerate the development, clinical and industrial translation of gene therapy for multiple genetic diseases. This meeting was not only the formal launch of the project, but also an exchange meeting for experts from multiple clinical and academic institutions to conduct in-depth discussions on technology translation.
At the meeting, project leader Dr. Liang Junbin gave an overall report on the project, first explaining the research objectives and content of the project, and detailing the key technical problems the project will solve and the main acceptance indicators. At the same time, he reported the current accumulated progress of the project and the next work arrangement plan. Sun Yat-sen Memorial Hospital of Sun Yat-sen University and the First Affiliated Hospital of Guangxi Medical University, the joint applicant units of the project, also gave introductions on their respective clinical research parts.
The expert institutions participating in the project kick-off meeting included the 923rd Hospital of the PLA, the First Affiliated Hospital of Sun Yat-sen University, Southern Medical University, Guangdong Pharmaceutical University and the Guangzhou Institutes of Biomedicine and Health of the Chinese Academy of Sciences. The attending experts discussed the overall scheme design and stage data of the project, conducted in-depth discussions on the research content and scheme of the project, and put forward pertinent and professional suggestions on overall coordination, task node control and assessment indicator completion during project implementation.
Leaders from the Science and Technology Innovation Monitoring Research Center also gave guidance opinions and expectations on the management of this project at the meeting. It is believed that with scientific planning and effective execution, this project will succeed and bring significant benefits to society.
The successful holding of this project kick-off meeting laid a solid foundation for the successful implementation of the project. The R&D project is expected to promote gene editing drug products for blood genetic diseases to serve clinical practice as soon as possible, thereby reducing the health burden of blood genetic diseases on the country and patients, driving the industrialization of gene editing, and achieving greater economic and social benefits.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.